98%
921
2 minutes
20
Studies have been recently conducted to find pancreatic ductal adenocarcinoma (PDAC) in high-risk groups by identifying individuals with pancreatic cystic lesions and elderly people (> 50 years) with new-onset diabetes mellitus (NODM). We report the case of a 91-year-old woman in good health with pancreatic cysts, who firstly displayed a NODM and, one month later, a PDAC. A dehydration syndrome with polydipsia and asthenia led to her hospitalization. High levels of blood glucose and glycated hemoglobin were found. An abdomen US showed a minute pancreas with some cysts. Rehydration and insulin therapy led to a good glycemic compensation. One month after discharge, she displayed weight loss, diarrhea, and jaundice. On the second admission, high levels of total and direct bilirubin, indices of hepatic cholestasis, and Ca 19.9 were found. An abdomen contrast medium CT evidenced a nodule at the pancreatic head, suggesting a malignant lesion, and dilatation of both the Wirsung duct and the whole biliary tract. Despite the lack of a histological diagnosis, the absence of signs of local invasion, metastasis, and co-morbidities as well as the rapid clinical deterioration led us to propose surgical treatment. A few days later, a pancreatoduodenectomy was performed. The histologic examination showed a moderately differentiated (G2) PDAC. The TNM staging was IIA (pT3, N0, M0) (R0). Three weeks after, she was discharged with normal liver function tests, Ca 19.9 levels, and a good glycemic compensation with insulin therapy. Five years after surgical treatment, she is still doing well displaying a normal abdomen CT follow-up, normal blood tests, including Ca 19.9, and a good glycemic compensation. Our case report denotes an exceptional duration of survival of PDAC and highlights the importance to seek its presence in every case of NODM in patients > 50 years, especially if they carry pancreatic cysts.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759095 | PMC |
http://dx.doi.org/10.7759/cureus.31608 | DOI Listing |
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group (≥ 70 years).
Cureus
August 2025
Department of Family Medicine, King Saud Medical City, Riyadh, SAU.
Background: Insulin overbasalization, which refers to the excessive use of basal insulin despite achieving target fasting glucose levels, poses significant clinical risks in managing type 2 diabetes mellitus. This practice can lead to adverse outcomes such as increased hypoglycemia, weight gain, and complications in glycemic control, which ultimately affect the patient's quality of life. Studies indicate that approximately 25-30% of patients on insulin therapy may experience overbasalization, highlighting the urgency of addressing this issue.
View Article and Find Full Text PDFPediatr Diabetes
September 2025
Pediatric Endocrinology Department, Gaafar Ibn Auf Pediatric Tertiary Hospital, Khartoum, Sudan.
Mauriac syndrome (MS) is a rare condition linked to inadequate glycemic control in type 1 diabetes mellitus (T1DM) and has also rarely been reported in patients with neonatal diabetes. MS manifests as growth failure, delayed puberty, cushingoid features, and hepatomegaly. The condition can be associated with complications like dyslipidemia, retinopathy, and nephropathy.
View Article and Find Full Text PDFCardiovasc Diabetol
August 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.
Background And Objective: The metabolic benefits of sodium-glucose co-transporter 2 inhibitors in clinical application are well established; however, there is dearth of knowledge on their impact on adipokine regulation. This study investigated the effect of enavogliflozin on adiponectin and leptin in patients with type 2 diabetes.
Methods: This secondary analysis of a phase III randomized, double-blind, placebo-controlled trial evaluated changes in serum adiponectin and leptin over 24 weeks.
Biomed Chromatogr
October 2025
Department of Medical Research, Air Force Medical Center, Air Force Medical University, Beijing, China.
Hemoglobin A (HbA) plays a role in the diagnosis and assessment of glycemic control in patients with diabetes. However, few studies have focused on the preparation methods and analytical performance evaluation of different formulations of mobile-phase buffers for HbA assays. In this study, mobile-phase buffers of new formulations were prepared for the measurement of HbA.
View Article and Find Full Text PDF